Stuart's Scan Journey, Protocol Updates & Community Insights

Stuart Briscoe shared an important update as he headed to MD Anderson for a major round of scans — a PET/CT, a full-spine MRI, and meetings with his medical team to review his ongoing protocol. His posts became a rolling diary of testing, waiting, and raw honesty about what’s working, what isn’t, and what’s next.

From plans to integrate CDS and DMSO, to conversations about immunotherapy (Anktiva) and cancer stem cell (CSC) theory, the thread evolved into a powerful look at what it means to actively build — and adapt — your own protocol while seeking cutting-edge support.

✅ Key Protocol Components Shared

Stuart Briscoe: Shared his ongoing protocol layers, including topical DMSO (50% solution with ivermectin) applied to his cervical region, plans to begin CDS when he returned home, and ongoing exploration of IV DMSO options.
Plan B strategy: Considering Anktiva (ImmunityBio), an immune-modulating drug designed to activate NK and T cells, while continuing with metabolic foundations.
Added DMSO in the past few weeks, noting its potential to help penetrate tumor tissue and deliver other agents.

✅ Scientific & Philosophical Insights

Stuart highlighted Dr. Paul Marik’s theory that cancer stem cells (CSCs) must be targeted to prevent recurrence, aligning with metabolic oncology’s push to address tumor “roots,” not just visible masses.
The thread discussed lymphopenia (low lymphocyte counts), a major immune-suppressive effect of chemo/radiation. Stuart linked this to Anktiva’s rationale: boosting immune capacity when conventional therapies have stripped it.
He stressed the balance between open-minded investigation and healthy skepticism — acknowledging both the promise and controversy around new interventions like Anktiva and CDS.

✅ Practical Wisdom from Community

Bernardo, Fitch, William, Trish, and Leonor sent messages of support, reinforcing how essential community encouragement is during testing weeks.
Lemon raised caution about Patrick Soon-Shiong, the founder of ImmunityBio (maker of Anktiva), noting his heavy investments in vaccine manufacturing and urging critical evaluation of his motives.
Odette Rocha suggested Dr. Susan Raj in India for expertise on CDS/DMSO protocols and encouraged careful sourcing and medical guidance.

✅ Resources & References Shared

Stuart linked to ImmunityBio’s FDA announcement: https://immunitybio.com/immunitybio-receives-fda-expanded-access-authorization-for-landmark-treatment-of-lymphopenia-with-anktiva-the-cancer-bioshield-platform-in-patients-with-solid-tumors/
Mentions of Dr. Marik (CSCs focus) and Dr. Makis, who often combines low-dose chemo with repurposed drugs and metabolic therapy.
Community brought in conversations around CDS, IV DMSO, and other immunotherapy options.

✅ Key Takeaways

Stuart’s scans revealed mixed results: some tumors stable, others showed regression, while some new areas progressed — a reminder that protocols often create shifting landscapes rather than instant wins.
His protocol is layered and evolving: DMSO, CDS, ivermectin, and the possibility of adding Anktiva or other immunotherapies.
The thread illustrated the real-world complexity of decision-making: weighing promising therapies (like Anktiva) against the backgrounds of their creators (Patrick Soon-Shiong), and integrating advice from trusted peers.
Stuart’s openness provides a living case study in resilience, constant evaluation, and the mix of science, faith, and pragmatism that fuels long-haul healing journeys.

Original Post

0 comments